FLHLF News and Press, Filament Health From 12/15/22

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc ( CSE:PSYG |...

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE Canada NewsWire The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament's natural psilocybin drug candidate PEX010 25mg ...

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be ...

VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical stage natural psychedelic drug development company, today announced that Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferences.com...

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES Canada NewsWire Filament's industry-leading IP portfolio now consists of ten patents for methods of extracting and standardizing natural psychedelic compounds VANCOUVER, BC , Nov. 30, 2022 /CNW/...

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Canada NewsWire CAMH to use Filament's natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC , ...

Filament Health press release ( OTCQB:FLHLF ): Q3 cash and cash equivalents of $3.5 million as of September 30, 2022. For further details see: Filament Health reports Q3 results

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Nov. 10, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-sta...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE Canada NewsWire Attendees will gain insight into the Company's clinical trials, partnership network, and growth plans VANCOUVER, BC , Oct. 12, 2022 /CNW/ - Filament Health Corp. (OTCQB: ...

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary o...